Lipoprotein(a) Is the Inherited Heart Attack Risk 1.4 Billion People Carry: Inside the RNA Therapies Racing to Silence It

For most of cardiology’s modern history, the story of heart disease has been the story of LDL cholesterol. Lower the LDL, lower the risk. Statins, ezetimibe, PCSK9 inhibitors, and now gene editing platforms like Verve Therapeutics have made that equation increasingly programmable. Yet millions of people who do everything right, who drive LDL into the floor, who exercise, who eat well, who never smoke, still have heart attacks in their forties and fifties. For a growing number of cardiologists, the explanation sits in a single blood test that most adults have never had done. It is lipoprotein(a), pronounced lipoprotein little a and abbreviated Lp(a). And in 2026, after more than sixty years of scientific frustration, it is finally becoming a treatable condition.

Presented By Our Partners

This is the deep dive on where Lp(a) science stands right now, the four RNA based therapies in late stage trials, what the first outcomes data is expected to show, and what patients and clinicians should do while the field waits for the evidence that could change global cardiovascular prevention.

The Risk Factor Hiding in Plain Sight

Lipoprotein(a) was first described in 1963 by the Norwegian geneticist Kare Berg. Structurally it is an LDL particle with an extra protein, apolipoprotein(a), wrapped around it by a disulfide bond. That extra protein changes everything. It makes the particle stickier inside arterial walls, more prone to driving plaque formation, more inflammatory, and uniquely capable of interfering with the body’s natural clot dissolving machinery because apolipoprotein(a) structurally mimics plasminogen. The result is a particle that is simultaneously atherogenic, thrombogenic, and pro inflammatory, a triple threat that operates independently of traditional LDL.

Your Lp(a) level is roughly 80 to 90 percent determined by your genetics, specifically by variation in the LPA gene on chromosome 6. It is set for life by early childhood, essentially unmoved by diet, exercise, weight loss, or statin therapy. In fact, statins tend to raise Lp(a) modestly in many patients. The major 2022 consensus statement from the European Atherosclerosis Society, led by Florian Kronenberg at the Medical University of Innsbruck and published in the European Heart Journal, concluded that Lp(a) is a causal, independent, and genetically determined risk factor for atherosclerotic cardiovascular disease and calcific aortic valve stenosis. Mendelian randomization studies from the Copenhagen General Population Study, led by Borge Nordestgaard, have repeatedly confirmed the causal link. People who inherit genetic variants that produce high Lp(a) have substantially higher rates of heart attack, stroke, peripheral artery disease, and aortic stenosis. Those who inherit variants producing low Lp(a) are protected.

The scale of the problem is staggering. Roughly one in five people globally, about 1.4 billion adults, carries an Lp(a) level high enough to meaningfully raise cardiovascular risk. Prevalence varies significantly by ancestry. Studies from the UK Biobank and the Dallas Heart Study have shown that people of African ancestry tend to have substantially higher Lp(a) levels on average than people of European ancestry, while South Asian populations also show elevated prevalence. Yet despite its scale, Lp(a) is tested in a small minority of adults. A 2024 analysis of electronic health records across large US health systems, published in the Journal of the American College of Cardiology, estimated that fewer than 3 percent of adults have ever had an Lp(a) test on record.

The 2026 Guidelines Shift

That is changing quickly. The 2024 National Lipid Association scientific statement, the 2022 European Atherosclerosis Society consensus, and the updated 2026 ACC and AHA cardiovascular prevention guidelines now recommend universal Lp(a) screening at least once in a lifetime for every adult, with earlier testing in anyone with a family history of premature heart disease or personal history of atherosclerotic events. The rationale is simple. Because Lp(a) is genetically determined and stable across life, a single measurement in adulthood gives a lifelong risk estimate that can reshape prevention strategy. A young adult with an Lp(a) of 150 nmol/L has a cardiovascular risk profile closer to a sixty year old smoker than to their peers, and that information should cascade into more aggressive LDL lowering, earlier initiation of therapy, lifestyle intensification, and screening of first degree relatives.

The challenge has always been that identifying the risk did not help you treat it. Niacin, long touted as the only intervention that modestly lowers Lp(a), failed to improve cardiovascular outcomes in the AIM HIGH and HPS2 THRIVE trials. PCSK9 inhibitors like evolocumab and alirocumab lower Lp(a) by roughly 20 to 30 percent but were not designed as Lp(a) therapies and are not adequate for the highest risk patients. Apheresis, the mechanical filtering of Lp(a) out of the blood, works but is expensive, time intensive, and available only in select centers for select patients.

What cardiologists needed was a therapy that specifically targeted Lp(a) production at the genetic level. In the last three years, that therapy has finally arrived.

Four Drugs, One Mechanism, A New Class of Medicine

Four drugs are now in advanced clinical development, all of them using some form of RNA based gene silencing to knock down production of apolipoprotein(a) directly at the liver. Three are small interfering RNA therapies, known as siRNAs. One is an antisense oligonucleotide, or ASO. All of them operate at the messenger RNA level, preventing the liver from producing the apolipoprotein(a) component of Lp(a) in the first place, which in turn collapses circulating Lp(a) to previously unseen levels.

Pelacarsen, developed by Ionis Pharmaceuticals and licensed to Novartis, is the furthest along. It is a GalNAc conjugated antisense oligonucleotide given as a monthly subcutaneous injection. In the Phase 2 trial published in the New England Journal of Medicine in 2020, pelacarsen reduced Lp(a) by up to 80 percent at the highest dose. It is now being tested in the Lp(a) HORIZON cardiovascular outcomes trial, a 8,300 patient study led by Steven Nissen at Cleveland Clinic, which is expected to report primary results in 2026. Lp(a) HORIZON is the first large trial designed to answer the question cardiology has been waiting decades for. If you dramatically lower Lp(a), do cardiovascular events fall?

Featured Partner

Invest in the Infrastructure Behind Modern Medicine

As healthcare expands beyond hospital walls, the buildings and campuses supporting that shift are generating compelling returns for investors who move early. The Healthcare Real Estate Fund offers qualified investors direct access to a curated portfolio of medical office, outpatient, and specialty care facilities.

Learn More →

Olpasiran, developed by Amgen, is an siRNA given by subcutaneous injection every 12 weeks. The Phase 2 OCEAN(a) DOSE trial, published in the New England Journal of Medicine in 2022 and led by Michelle O’Donoghue at Brigham and Women’s Hospital, showed Lp(a) reductions of 95 to 98 percent with the highest doses. A Phase 3 outcomes trial called OCEAN(a) OUTCOMES is fully enrolled and expected to report later this decade.

Lepodisiran, developed by Eli Lilly, is another siRNA designed for exceptionally long duration action. In the ALPACA trial results presented at the 2025 American College of Cardiology Scientific Sessions and published in the New England Journal of Medicine, lepodisiran produced a mean reduction in Lp(a) of roughly 94 percent, with a single 400 mg dose suppressing Lp(a) for more than 180 days. Lilly’s Phase 3 ACCLAIM Lp(a) cardiovascular outcomes trial is now underway.

Zerlasiran, developed by Silence Therapeutics, is the fourth contender. In Phase 2 data published in JAMA in 2024, zerlasiran delivered approximately 80 to 90 percent reductions in Lp(a) with dosing as infrequent as every 24 weeks. Silence has partnered with Eli Lilly and is moving into later stage development.

These results are not incremental. For comparison, statins reduce LDL cholesterol by 25 to 55 percent. PCSK9 inhibitors add another 50 to 60 percent on top. Those are the numbers that defined the last generation of cardiovascular medicine. The new RNA therapies for Lp(a) are producing 80 to 95 percent reductions in a target that, until now, had no effective treatment at all. If these reductions translate into proportional reductions in cardiovascular events, Lp(a) targeting would arguably become the most impactful prevention advance since the first statin trials.

What the Outcomes Data Needs to Show

There is still a scientific question that must be answered, and it matters enormously. Mendelian randomization evidence is consistent that lifelong low Lp(a) protects against cardiovascular disease. But whether lowering Lp(a) starting in midlife, after decades of exposure and plaque accumulation, will translate into proportional event reductions remains the crucial empirical question.

Lp(a) HORIZON is powered to detect a 17 percent relative risk reduction in major adverse cardiovascular events over roughly four years of treatment. Modeling work by Sotirios Tsimikas at the University of California San Diego, who helped develop pelacarsen, suggests that the effect may in fact be substantially larger in patients with the highest baseline Lp(a) levels, because they have the most to gain. But cardiology has been burned before. CETP inhibitors raised HDL and lowered LDL yet failed to improve outcomes in multiple trials. Niacin improved lipid profiles and failed twice. The lesson is that the right biomarker movement does not automatically mean clinical benefit. Lp(a) HORIZON’s readout in 2026 is therefore the single most anticipated cardiovascular trial of the year.

If the trial is positive, pelacarsen will become the first approved Lp(a) lowering therapy in history, and the regulatory and clinical pathway for the siRNA competitors will clear rapidly. If the trial is negative or modestly positive, the field will have to grapple with whether the problem is insufficient magnitude of reduction, insufficient duration of exposure, the wrong patient population, or a more fundamental limit on what late life intervention can achieve against a lifelong risk factor.

The Ecosystem of Lp(a) Prevention

While the outcomes trials run, the ecosystem around Lp(a) is already transforming. Universal screening recommendations are reshaping clinical workflows. Major health systems including Cleveland Clinic, Mount Sinai, Stanford Preventive Cardiology, and the Lp(a) Foundation clinical network have launched dedicated Lp(a) clinics that combine testing, risk stratification, aggressive LDL lowering, lifestyle intensification, and enrollment in ongoing trials. Genetic counselors are increasingly integrated into lipid clinics because an elevated Lp(a) in one family member has immediate implications for siblings and children. Electronic health record alerts in several large systems now flag patients with documented Lp(a) levels above 125 nmol/L for intensified prevention protocols.

Patient advocacy has also grown dramatically. Organizations like the Family Heart Foundation and the Lipoprotein(a) Foundation have educated a generation of high risk patients about a risk factor their doctors never mentioned. The result is that many patients walk into cardiology appointments already knowing their Lp(a) level, already knowing their family history, and already asking about clinical trial enrollment.

The cost question remains open. RNA therapies for rare cardiovascular conditions have tended to carry six figure annual price tags at launch. Lp(a) targeting is not a rare condition. If the price is set for the rare disease market, the drugs will only reach a small slice of the 1.4 billion people they could help. If the price is set for population scale prevention, payers, governments, and employers will face a cost curve unlike any cardiovascular intervention to date. How this is resolved will be as important to real world impact as any clinical trial.

Where This Sits in the Longevity Frame

Healthcare Discovery readers will recognize the pattern. A specific biological mechanism, identified decades ago and long considered untreatable, becomes suddenly targetable through a new modality. siRNA and antisense therapeutics have already transformed familial amyloidosis with inotersen and patisiran, transformed hereditary attack angioedema with new prophylactic therapies, and are now entering cardiovascular medicine at scale. Inclisiran, the PCSK9 targeting siRNA, is already approved and used widely. The Lp(a) class extends that platform into the largest cardiovascular risk factor for which we have had no specific therapy.

From a longevity science perspective, Lp(a) matters because cardiovascular disease remains the leading cause of death globally and the single biggest drag on healthspan in aging populations. A prevention tool that removes a genetically fixed risk factor from the equation for a billion people is, in healthspan terms, one of the largest possible levers. It sits alongside GLP-1 receptor agonists for metabolic disease, CRISPR based cholesterol editing for LDL, and resistance training and VO2 max interventions for sarcopenia and cardiorespiratory reserve, as part of an integrated toolkit for extending disease free years.

What This Means For You

If you have never had an Lp(a) test, ask for one. It is a single blood draw, inexpensive, and typically requires only one measurement in a lifetime because the level is genetically determined and stable. Most US insurance plans now cover it, and the 2026 ACC and AHA prevention guidelines support universal screening at least once.

If your Lp(a) is elevated, usually defined as above 75 nmol/L or 30 mg/dL with higher risk at levels above 125 nmol/L, treat it as actionable information rather than a sentence. Talk to a cardiologist or lipid specialist. Your first line strategy should include aggressive lowering of LDL cholesterol, because LDL and Lp(a) risks are additive. That often means earlier initiation of statins, addition of ezetimibe, and consideration of PCSK9 inhibitors if you are not reaching targets. Blood pressure and blood sugar control matter even more than usual. If you smoke, stopping becomes urgent rather than important.

Ask about clinical trials. Lp(a) HORIZON, OCEAN(a) OUTCOMES, and ACCLAIM Lp(a) are actively enrolling or have recently enrolled patients at sites across North America, Europe, and Asia. Trial participation may give you access to an Lp(a) specific therapy years before commercial approval.

Screen your family. If your Lp(a) is high, there is roughly a 50 percent chance that each of your first degree relatives, parents, siblings, and children, also has elevated Lp(a). A single test in each of them turns a family history of unexplained heart disease into a treatable pattern.

Finally, stay engaged with what comes out of Lp(a) HORIZON this year. If the data is positive, your conversations with your clinician in 2027 will look very different from your conversations today. A genetically determined risk factor that 1.4 billion people carry is about to become, for the first time in medical history, something your doctor can actually do something about. That is what it looks like when a longevity frontier closes.

Healthcare Discovery tracks the science and clinical translation of longevity medicine. This article reflects the state of the research as of April 2026. It is for educational purposes and is not medical advice. Discuss testing and treatment decisions with a licensed clinician.

Free Daily Briefing

The Latest Longevity Science.
Delivered Every Morning.

Join researchers, physicians, and health professionals getting daily breakthroughs in AI-driven medicine, epigenetics, and longevity research.

Support the research that powers this editorial

Subscribe Free

No spam. Unsubscribe anytime. We respect your inbox.